Antiarrhythmics

5-HT3 receptor antagonists, antiarrhythmics ---> SmPC of [granisetron] of EMA

5-HT3 receptor antagonists, such as granisetron, may be associated with arrhythmias or ECG abnormalities. This potentially may have clinical significance in patients who are being treated with antiarrhythmics or beta-blockers.

Abiraterone [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Since androgen deprivation treatment may prolong the QT interval, caution is advised when administering ZYTIGA with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes

Abiraterone [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Since androgen deprivation treatment may prolong the QT interval, caution is advised when administering ZYTIGA with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes

Acebutolol, class IA antiarrhythmic agents

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Acebutolol, class IB antiarrhythmic agents

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Acebutolol, class IC antiarrhythmic agents

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Acenocoumarol [1], antiarrhythmics ---> SmPC of [1] of eMC

The co-administration may enhance the anticoagulant effect of acenocoumarol and increase the bleeding risk

Adenosine [1], antiarrhythmics ---> SmPC of [1] of eMC

Adenosine may interact with drugs tending to impair cardiac conduction.

Ajmaline, antiarrhythmics

The combination of ajmaline with other antiarrhythmics may cause an additive inhibitory effect on the AV conduction, the intraventricular stimulus conduction and the force of contraction

Ajmaline, class IA antiarrhythmic agents

Ajmaline should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Ajmaline, class IB antiarrhythmic agents

Ajmaline should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Ajmaline, class IC antiarrhythmic agents

Ajmaline should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Aliskiren/amlodipine/hydrochlorothiazide [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Aliskiren/amlodipine/hydrochlorothiazide [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Aliskiren/hydrochlorothiazide [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes

Aliskiren/hydrochlorothiazide [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes

Amantadine, class IA antiarrhythmic agents

The co-administration of amantadine with drugs that prolong the QT interval is contraindicated

Amantadine, class III antiarrhythmic agents

The co-administration of amantadine with drugs that prolong the QT interval is contraindicated

Amiodarone [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

The combined therapy of amiodarone with drugs which prolong the QT interval is contra-indicated due to the increased risk of torsades de pointes

Amiodarone, antiarrhythmics

The use of amiodarone with other antiarrhythmics or arrhytmogenic medicinal products may increase the incidence of cardiac arrhythmias and should be avoided

Amisulpride [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Caution is advised when prescribing amisulpride with medicines known to prolong the QT interval

Amisulpride [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

Caution is advised when prescribing amisulpride with medicines known to prolong the QT interval

Amitriptyline [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

There is an increased risk of ventricular arrhythmias with drugs which prolong the QT interval. Concomitant use should be avoided

Amitriptyline [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

There is an increased risk of ventricular arrhythmias with drugs which prolong the QT interval. Concomitant use should be avoided

Amitriptylinoxide, class IA antiarrhythmic agents

The concomitant use of drugs that also prolong the QT interval has to be avoided

Amitriptylinoxide, class III antiarrhythmic agents

The concomitant use of drugs that also prolong the QT interval has to be avoided

Amlodipine/valsartan/hydrochlorothiazide [1], antiarrhythmics ---> SmPC of [1] of EMA

The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of antiarrhythmics. If these medicines are to be prescribed with amlodipine/valsartan/hydrochlorothiazide, monitoring of potassium plasma levels is advised.

Amlodipine/valsartan/hydrochlorothiazide [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.

Amlodipine/valsartan/hydrochlorothiazide [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.

Antiarrhythmics, atenolol

Enhanced cardiodepressant effect of atenolol

Antiarrhythmics, atracurium [2] ---> SmPC of [2] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with antiarrhythmic medicinal products

Antiarrhythmics, betablockers

The co-administration may cause additive effects resulting in hypotension, and/or marked bradycardia

Antiarrhythmics, betaxolol

The co-administration may cause additive effects resulting in hypotension, and/or marked bradycardia

Antiarrhythmics, bimatoprost/timolol [2] ---> SmPC of [2] of EMA

There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral anti-arrhythmics (including amiodarone)

Antiarrhythmics, bisacodyl

Hypokalaemia (described in association with chronic laxative abuse) interacts with antiarrhythmics (e. g. quinidine)

Antiarrhythmics, brinzolamide/timolol [2] ---> SmPC of [2] of EMA

There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral anti-arrhythmics (including amiodarone)

Antiarrhythmics, buckthorn berries

Potassium loss due to chronic use: May affect the effectiveness of antiarrhythmic agent

Antiarrhythmics, cabozantinib [2] ---> SmPC of [2] of EMA

Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.

Antiarrhythmics, calcium antagonists

Calcium antagonist may potentiate the negative inotrope effect of antiarrthymics leading to sinus arrest and AV block

Antiarrhythmics, carbamazepine

The co-administration may increase the risk of cardiac conduction abnormalities

Antiarrhythmics, carteolol [2] ---> SmPC of [2] of eMC

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with antiarrhythmics (including amiodarone)

Antiarrhythmics, cascara bark

Potassium loss due to chronic use: May affect the effectiveness of antiarrhythmic agent

Antiarrhythmics, cisatracurium [2] ---> SmPC of [2] of eMC

Antiarrhythmics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents

Antiarrhythmics, diltiazem [2] ---> SmPC of [2] of eMC

Concomitant prescription of diltiazem with other antiarrhythmic agents is not recommended (additive risk of increased cardiac adverse effects).

Antiarrhythmics, disopyramide

Concomitant administration of disopyramide with other anti-arrhythmic drugs is contra-indicated except under certain circumstances

Antiarrhythmics, disopyramide [2] ---> SmPC of [2] of eMC

Concomitant administration of disopyramide with other anti-arrhythmic drugs is contra-indicated except under certain circumstances

Antiarrhythmics, distigmine

Decreased distigmine effect

Antiarrhythmics, dorzolamide/timolol [2] ---> SmPC of [2] of eMC

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic betablockers solution is administered concomitantly with antiarrhythmics

Antiarrhythmics, doxylamine

Concomitant use of doxylamine with drugs that prolong the QT interval should be avoided

Antiarrhythmics, felodipine/metoprolol

Class I anti-arrhythmic drugs may have potentiating effects on atrial-conduction time and induce negative inotropic effect of metoprolol.

Antiarrhythmics, frangula bark

Potassium loss due to chronic use: May affect the effectiveness of antiarrhythmic agent

Antiarrhythmics, gallopamil

Mutual enhancement of cardiovascular effects. The i.v. administration of antiarrhythmics during gallopamil therapy is contraindicated (except intensive care)

Antiarrhythmics, guanethidine

Concurrent administration of guanethidine with anti-arrhythmic agents and digitalis may lead to sinus bradycardia.

Antiarrhythmics, latanoprost/timolol [2] ---> SmPC of [2] of eMC

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with antiarrhythmics (including amiodarone)

Antiarrhythmics, laxatives

The chronic use of laxatives may cause hypokaliemia, which increases the risk of heart rhythm disorders.

Antiarrhythmics, levobunolol [2] ---> SmPC of [2] of eMC

There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blocker solutions are administered concomitantly with anti-arrhythmics

Antiarrhythmics, lidocaine [2] ---> SmPC of [2] of eMC

Lidocaine should be used with caution in patients receiving agents structurally related to amide-type local anaesthetics (e.g. anti-arrhythmics, such as mexiletine), since the systemic toxic effects are additive.

Antiarrhythmics, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with medicinal products affected by serum potassium disturbances

Antiarrhythmics, maprotiline

Maprotiline may enhance the effect of antiarrhythmics, especially of type Ia (e. g. quinidine) and type III (e. g. amiodarone)

Antiarrhythmics, mefloquine

Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.

Antiarrhythmics, mepivacaine

The co-administration of mepivacaine with structurally related compounds (e. g. antiarrhythmics like aprindine, mexiletine) should be done with great care due to the adverse effects in these cases are additive

Antiarrhythmics, methyldopa

The co-administration may enhance the hypotensive effect

Antiarrhythmics, metildigoxin

Increased plasma levels of metildigoxin

Antiarrhythmics, metipranolol

Enhancement of cardiodepressant effect

Antiarrhythmics, mivacurium [2] ---> SmPC of [2] of eMC

As all non-depolarising neuromuscular blocking agents, the magnitude and/or duration of non-depolarising neuromuscular block may be increased and infusion requirements may be reduced as a result of interaction with anti-arrhythmic drugs

Antiarrhythmics, muscle relaxants (non-depolarizing) ---> SmPC of [atracurium] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with antiarrhythmic medicinal products

Antiarrhythmics, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Antiarrhythmics, nilotinib [2] ---> SmPC of [2] of EMA

Significant prolongation of the QT interval may occur when nilotinib is inappropriately taken with medicinal products with a known potential to prolong QT. Prolongation of the QT interval may expose patients to the risk of fatal outcome.

Antiarrhythmics, nitrendipine

Calcium antagonist may potentiate the negative inotrope effect of antiarrthymics leading to sinus arrest and AV block

Antiarrhythmics, panobinostat [2] ---> SmPC of [2] of EMA

Based on preclinical and clinical data, panobinostat has the potential to prolong the QT interval. Concomitant use of panobinostat and other substances that are known to prolong the QT interval is not recommended.

Antiarrhythmics, pazopanib [2] ---> SmPC of [2] of EMA

Pazopanib should be used with caution in patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medicinal products that may prolong QT interval and those with relevant pre-existing cardiac disease.

Antiarrhythmics, penbutolol

The co-administration of antiarrthymics and penbutolol may increase the tendency to cardiac conduction and rhythm disorders and cause strong hypotension

Antiarrhythmics, phenazone

Concomitant use of phenazone and antiarrhythmics delays the elimination of phenazone. There is the possibility of an accumulation

Antiarrhythmics, potassium citrate/potassium hydrogen carbonate [2] ---> SmPC of [2] of EMA

Periodic monitoring of plasma potassium and ECG is recommended when Sibnayal is administered with medicinal products affected by plasma potassium disturbances due to the potential risk for a pro-arrhythmic effect

Antiarrhythmics, prajmalium

With the co-administration of prajmalium with other antiarrhythmics is to expect an additive inhibitor effect on the AV-conduction, intraventricular conduction and contraction force

Antiarrhythmics, procainamide

The co-administration may cause cardiologic or antagonic effect. The toxicity may be additive

Antiarrhythmics, procaine

The co-administration may have an additive inhibiting effect on the AV conduction, intraventricular impulse spread and contractile force

Antiarrhythmics, propafenone

The co-administration may enhance the propafenone effect and cause cardiodepressant effects

Antiarrhythmics, quinidine

The concomitant use may increase the risk of cardiac arrhythmia

Antiarrhythmics, quinidine

The chronic use of laxatives may cause hypokaliemia, which increases the risk of heart rhythm disorders.

Antiarrhythmics, ribociclib [2] ---> SmPC of [2] of EMA

Co-administration of Kisqali with medicinal products with a known potential to prolong the QT interval such as anti-arrhythmic medicinal products should be avoided

Antiarrhythmics, salbutamol

The co-administration of salbutamol and antiarrhythmic agents (e.g. digitalis glycoside and quinidine) may increase the risk of adverse effects

Antiarrhythmics, senna

The chronic use of laxatives may cause hypokaliemia, which increases the risk of heart rhythm disorders.

Antiarrhythmics, sevelamer

Caution should be exercised when prescribing sevelamer to patients also taking anti-arrhythmic medications

Antiarrhythmics, sevelamer carbonate [2] ---> SmPC of [2] of EMA

Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials.

Antiarrhythmics, sevelamer hydrochloride [2] ---> SmPC of [2] of EMA

Caution should be exercised when prescribing sevelamer hydrochloride to patients also taking anti-arrhythmics.

Antiarrhythmics, sodium picosulfate

Hypokaliemia may be a risk of torsades de pointes in patients treated with antiarrhythmics

Antiarrhythmics, sunitinib [2] ---> SmPC of [2] of EMA

Sunitinib should be used with caution in patients with a known history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.

Antiarrhythmics, terbutaline

The co-administration may cause cardiac rhythm disorders

Antiarrhythmics, timolol ---> SmPC of [bimatoprost/timolol] of EMA

There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral anti-arrhythmics (including amiodarone)

Antiarrhythmics, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

The concurrent use of verapamil and cardiodepressives, i.e., medicinal products that inhibit cardiac impulse generation and conduction, may produce undesirable additive effects

Antiarrhythmics, travoprost/timolol [2] ---> SmPC of [2] of EMA

The potential exists for additive effects and production of hypotension and/or marked bradycardia.

Antiarrhythmics, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC

Tricyclic antidepressants should not be employed in combination with antiarrhythmic agents that are strong CYP2D6 inhibitors

Antiarrhythmics, verapamil [2] ---> SmPC of [2] of eMC

The combination of anti-arrhythmic agents with verapamil may lead to additive cardiovascular effects (e.g. AV block, bradycardia, hypotension, heart failure).

Apalutamide [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Erleada with medicinal products able to induce Torsade de pointes should be carefully evaluated

Apalutamide [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Erleada with medicinal products able to induce Torsade de pointes should be carefully evaluated

Arsenic trioxide [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Caution is advised when arsenic trioxide is coadministered with other medicinal products known to cause QT/QTc interval prolongation

Arsenic trioxide [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Caution is advised when arsenic trioxide is coadministered with other medicinal products known to cause QT/QTc interval prolongation

Artemether, class IA antiarrhythmic agents

The co-administration of medicinal products that prolong the interval QT is contraindicated

Artemether, class III antiarrhythmic agents

The co-administration of medicinal products that prolong the interval QT is contraindicated

Artemether/lumefantrine [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Artemether/lumefantrine is contraindicated in patients taking drugs that are known to prolong the QTc interval.

Artemether/lumefantrine [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

Artemether/lumefantrine is contraindicated in patients taking drugs that are known to prolong the QTc interval.

Atenolol [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Caution should be exercised when prescribing a beta-adrenoceptor blocking drug with class I antiarrhythmic agents.

Atenolol [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Caution should be exercised when prescribing a beta-adrenoceptor blocking drug with class I antiarrhythmic agents.

Atenolol [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Caution should be exercised when prescribing a beta-adrenoceptor blocking drug with class I antiarrhythmic agents.

Atenolol/chlortalidone [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atenolol/chlortalidone [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atenolol/chlortalidone [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atenolol/nifedipine [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs (eg, disopyramide) with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atenolol/nifedipine [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs (eg, disopyramide) with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atenolol/nifedipine [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Class I anti-arrhythmic drugs (eg, disopyramide) with atenolol may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.

Atomoxetine, class IA antiarrhythmic agents

There is the potential for an increased risk of QT interval prolongation when atomoxetine is administered with other QT prolonging drugs

Atomoxetine, class III antiarrhythmic agents

There is the potential for an increased risk of QT interval prolongation when atomoxetine is administered with other QT prolonging drugs

Azithromycin [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Azithromycin should be used with caution in patients currently receiving treatment with other active substances known to prolong QT interval

Azithromycin [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

Azithromycin should be used with caution in patients currently receiving treatment with other active substances known to prolong QT interval

Betablockers, class I antiarrhythmic agents ---> SmPC of [propranolol] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Betablockers, class IA antiarrhythmic agents ---> SmPC of [propranolol] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Betablockers, class IB antiarrhythmic agents ---> SmPC of [propranolol] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Betablockers, class IC antiarrhythmic agents ---> SmPC of [propranolol] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Betablockers, class III antiarrhythmic agents

The concomitant use should be done with caution as the effect on atrioventricular conduction time may be potentiated

Betaxolol, class IA antiarrhythmic agents

The combination may cause alterations of contractibility and stimulus conduction by suppression of sympathetic compensatory mechanisms

Bisoprolol [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Class I antiarrhythmic may potentiate the effect on atrio-ventricular conduction time and increase the negative inotropic effect

Bisoprolol [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Class I antiarrhythmic may potentiate the effect on atrio-ventricular conduction time and increase the negative inotropic effect

Bisoprolol [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Class I antiarrhythmic may potentiate the effect on atrio-ventricular conduction time and increase the negative inotropic effect

Bisoprolol [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

The combination of class-III antiarrhythmic medicinal products with bisoprolol may potentiate the effect on atrio-ventricular conduction time

Bosutinib [1], class IA antiarrhythmic agents ---> SmPC of [1] of EMA

Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products or other medicinal products that may lead to QT prolongation

Bosutinib [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Bosutinib should be used with caution in patients who have or may develop prolongation of QT, including those patients taking anti-arrhythmic medicinal products or other medicinal products that may lead to QT prolongation

Budipine, class IA antiarrhythmic agents

The co-administration of budipine with drugs known to prolong QT interval is contraindicated

Budipine, class III antiarrhythmic agents

The co-administration of budipine with drugs known to prolong QT interval is contraindicated

Bumetanide, class IA antiarrhythmic agents

Hypokalaemia increases the risk of QT interval prolongation and torsades de pointes of class Ia antiarrhythmics

Bumetanide, class III antiarrhythmic agents

Hypokalaemia increases the risk of QT interval prolongation and torsades de pointes of class III antiarrhythmics

Bupivacaine, class III antiarrhythmic agents [2] ---> SmPC of [2] of eMC

Specific interaction studies with bupivacaine and class III anti-arrhythmic drugs (e.g. amiodarone) have not been performed, but caution is advised.

Carteolol [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

The co-administration increases the risk of heart rhythm disorders, particularly torsades de pointes

Carteolol, class III antiarrhythmic agents

The co-administration increases the risk of heart rhythm disorders, particularly torsades de pointes

Carvedilol [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Close monitoring should be done in case of co-administration of carvedilol and class I antiarrhythmics. There is a risk of cardiac failure in case of class Ia antiarrhythmics concomitant intravenous therapy.

Carvedilol [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Close monitoring should be done in case of co-administration of carvedilol and class I antiarrhythmics.

Carvedilol [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Close monitoring should be done in case of co-administration of carvedilol and class I antiarrhythmics. There is a risk of cardiac failure in case of class Ic antiarrhythmics concomitant intravenous therapy.

Celiprolol [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Care should be taken in prescribing beta-adrenoceptor blockers with Class I antiarrhythmic agents, since these agents may potentiate the negative effects on A-V conduction and myocardial contractility.

Celiprolol [1], class IB antiarrhythmic agents ---> SmPC of [1] of eMC

Care should be taken in prescribing beta-adrenoceptor blockers with Class I antiarrhythmic agents, since these agents may potentiate the negative effects on A-V conduction and myocardial contractility.

Celiprolol [1], class IC antiarrhythmic agents ---> SmPC of [1] of eMC

Care should be taken in prescribing beta-adrenoceptor blockers with Class I antiarrhythmic agents, since these agents may potentiate the negative effects on A-V conduction and myocardial contractility.

Ceritinib [1], class I antiarrhythmic agents ---> SmPC of [1] of EMA

Ceritinib should be used with caution in patients taking other medicinal products that may lead to QT prolongation. Monitoring of the QT interval is indicated in the event of combinations of such medicinal products

Ceritinib [1], class III antiarrhythmic agents ---> SmPC of [1] of EMA

Ceritinib should be used with caution in patients taking other medicinal products that may lead to QT prolongation. Monitoring of the QT interval is indicated in the event of combinations of such medicinal products

Chloral hydrate, class IA antiarrhythmic agents

Concomitant use of chloral hydrate with drugs known to also prolong the QT interval should be avoided

Chloral hydrate, class III antiarrhythmic agents

Concomitant use of chloral hydrate with drugs known to also prolong the QT interval should be avoided

Chlorpromazine [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

There is an increased risk of arrhythmias when chlorpromazine is used concomitant with QT prolonging drugs. The combination is not recommended

Chlorpromazine [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

There is an increased risk of arrhythmias when chlorpromazine is used concomitant with QT prolonging drugs. The combination is not recommended

Chlorprothixene, class IA antiarrhythmic agents

The concurrent use of chlorprothixene and drugs that also prolong the QT interval should be avoided

Chlorprothixene, class III antiarrhythmic agents

The concurrent use of chlorprothixene and drugs that also prolong the QT interval should be avoided

Cimetidine [1], class I antiarrhythmic agents ---> SmPC of [1] of eMC

Cimetidine, enzyme inhibitor, may increase the plasma levels of antiarrhythmic agent

Ciprofloxacin, class IA antiarrhythmic agents [2] ---> SmPC of [2] of eMC

Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval

Ciprofloxacin, class III antiarrhythmic agents [2] ---> SmPC of [2] of eMC

Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval

Cisapride, class IA antiarrhythmic agents

The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated

Cisapride, class III antiarrhythmic agents

The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated

Citalopram [1], class IA antiarrhythmic agents ---> SmPC of [1] of eMC

Co-administration of citalopram with medicinal products that prolong the QT interval is contraindicated

Citalopram [1], class III antiarrhythmic agents ---> SmPC of [1] of eMC

Co-administration of citalopram with medicinal products that prolong the QT interval is contraindicated

Class I antiarrhythmic agents, disopyramide [2] ---> SmPC of [2] of eMC

Antiarrhythmic combination should be avoided except under certain circumstances

Class I antiarrhythmic agents, dronedarone [2] ---> SmPC of [2] of EMA

Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias

Class I antiarrhythmic agents, esmolol [2] ---> SmPC of [2] of eMC

Concomitant use of esmolol and class I antiarrhythmic agents can increase the action of both on the AV-conductance time and induce negative inotropic effect.

Class I antiarrhythmic agents, fluconazole

Cases of QTc interval prolongation and/ or torsades de pointes may occur after concomitant use of fluconazole with some anti-arrhythmics.

Class I antiarrhythmic agents, labetalol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class I antiarrhythmic agents, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Class I antiarrhythmic agents, nebivolol [2] ---> SmPC of [2] of eMC

Combination not recommended as the effect on atrio-ventricular conduction time may be potentiated and the negative inotropic effect increased

Class I antiarrhythmic agents, oxprenolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class I antiarrhythmic agents, pindolol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class I antiarrhythmic agents, pindolol/clopamide

Caution should be exercised in the concurrent use of beta-blocking agents with class 1 antiarrhythmics (e.g. disopyramide, quinidine) and amiodarone.

Class I antiarrhythmic agents, propranolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class I antiarrhythmic agents, terfenadine

The co-administration of terfenadine with antiarrthymics of class I or III is contraindicated

Class IA antiarrhythmic agents [1], flupentixol ---> SmPC of [1] of eMC

Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided.

Class IA antiarrhythmic agents, clomipramine [2] ---> SmPC of [2] of eMC

The risk of QTc prolongation and Torsade de Pointes is likely to be increased if clomipramine is co-administered with other drugs that can cause QTc prolongation. Therefore concomitant use is not recommended

Class IA antiarrhythmic agents, crizotinib [2] ---> SmPC of [2] of EMA

Concomitant use of crizotinib (prolongs QT interval) with medicinal products known to prolong QT interval or medicinal products able to induce Torsades de pointes should be carefully considered.

Class IA antiarrhythmic agents, darolutamide [2] ---> SmPC of [2] of EMA

Since androgen deprivation treatment may prolong the QT interval, the co-administration with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes should be carefully evaluated.

Class IA antiarrhythmic agents, degarelix [2] ---> SmPC of [2] of EMA

The combination of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes should be carefully evaluated

Class IA antiarrhythmic agents, dimenhydrinate

The concurrent use of dimenhydrinate and drugs that also prolong the QT interval should be avoided

Class IA antiarrhythmic agents, diphenhydramine

The co-administration is contraindicated

Class IA antiarrhythmic agents, dofetilide [2] ---> SmPC of [2] of EMA

The co-administration of dofetilide with drugs known to prolong the QT interval is contraindicated

Class IA antiarrhythmic agents, doxepin

The co-administration of doxepin with drugs that can prolong the QT interval should be avoided

Class IA antiarrhythmic agents, dronedarone [2] ---> SmPC of [2] of EMA

Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias

Class IA antiarrhythmic agents, droperidol [2] ---> SmPC of [2] of eMC

Medicinal products known to prolong the QTc interval should not be concomitantly administered with droperidol.

Class IA antiarrhythmic agents, efavirenz/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes

Class IA antiarrhythmic agents, eliglustat [2] ---> SmPC of [2] of EMA

Because eliglustat is predicted to cause mild increases in ECG intervals at substantially elevated plasma concentrations, use of eliglustat should be avoided in combination with Class IA and Class III antiarrhythmic medicinal products.

Class IA antiarrhythmic agents, enzalutamide [2] ---> SmPC of [2] of EMA

The concomitant use of enzalutamide with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes should be carefully evaluated

Class IA antiarrhythmic agents, eribulin [2] ---> SmPC of [2] of EMA

ECG monitoring is recommended if therapy is initiated in patients with concomitant treatment with medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities.

Class IA antiarrhythmic agents, erythromycin

Patients receiving erythromycin concurrently with drugs which can cause prolongation of the QT interval should be carefully monitored; the concomitant use of erythromycin with some of these drugs is contraindicated

Class IA antiarrhythmic agents, escitalopram [2] ---> SmPC of [2] of eMC

Co-administration of escitalopram with medicinal products that prolong the QT-interval is contraindicated.

Class IA antiarrhythmic agents, esmolol [2] ---> SmPC of [2] of eMC

Concomitant use of esmolol and class I antiarrhythmic agents can increase the action of both on the AV-conductance time and induce negative inotropic effect.

Class IA antiarrhythmic agents, fingolimod [2] ---> SmPC of [2] of EMA

Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate because of the potential additive effects on heart rate

Class IA antiarrhythmic agents, flecainide [2] ---> SmPC of [2] of eMC

Flecainide should not be administered concomitantly with other class I antiarrhythmics.

Class IA antiarrhythmic agents, fluconazole

Cases of QTc interval prolongation and/ or torsades de pointes may occur after concomitant use of fluconazole with some anti-arrhythmics

Class IA antiarrhythmic agents, fluphenazine [2] ---> SmPC of [2] of eMC

The effect of fluphenazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs and fluphenazine is contraindicated.

Class IA antiarrhythmic agents, furosemide

Electrolyte imbalance may enhance the toxicity of antiarrhythmic agent. Monitoring of serum potassium and ECG is recommended

Class IA antiarrhythmic agents, gatifloxacin

The co-administration of gatifloxacin with medicinal products that prolong the QT interval should be avoided

Class IA antiarrhythmic agents, gemifloxacin

The co-administration of gemifloxacin with medicinal products that prolong the QT interval should be avoided

Class IA antiarrhythmic agents, haloperidol [2] ---> SmPC of [2] of eMC

Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended

Class IA antiarrhythmic agents, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Class IA antiarrhythmic agents, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Class IA antiarrhythmic agents, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Class IA antiarrhythmic agents, ibutilide

Possible prolongation of refractory period. Contraindicated: Combination, administration within 4 hours after infusion and only if the QTc has returned to its basal value

Class IA antiarrhythmic agents, imipramine [2] ---> SmPC of [2] of eMC

Tricyclic antidepressants should not be employed in combination with anti-arrhythmic agents of the quinidine type.

Class IA antiarrhythmic agents, indapamide [2] ---> SmPC of [2] of eMC

The co-administration may increase the risk of ventricular arrhythmias, particularly torsades de pointes (hypokalemia is a risk factor)

Class IA antiarrhythmic agents, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Class IA antiarrhythmic agents, labetalol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IA antiarrhythmic agents, lacosamide [2] ---> SmPC of [2] of EMA

Lacosamide should be used with caution in patients treated with class I antiarrhythmic drugs

Class IA antiarrhythmic agents, lenvatinib [2] ---> SmPC of [2] of EMA

Electrocardiograms should be monitored in patients taking medicinal products known to prolong the QT interval

Class IA antiarrhythmic agents, levofloxacin [2] ---> SmPC of [2] of EMA

Levofloxacin should be used with caution in patients receiving active substances known to prolong the QT interval

Class IA antiarrhythmic agents, levomepromazine [2] ---> SmPC of [2] of eMC

There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval

Class IA antiarrhythmic agents, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA

The risk of additional systemic toxicity should be considered when large doses of lidocaine/prilocaine are applied to patients already using other local anaesthetics or structurally related medicinal products

Class IA antiarrhythmic agents, lithium ---> SmPC of [lithium carbonate] of eMC

As a precautionary measure, lithium should be avoided in patients concomitantly treated with drugs that are known to prolong the QT interval

Class IA antiarrhythmic agents, lithium carbonate [2] ---> SmPC of [2] of eMC

As a precautionary measure, lithium should be avoided in patients concomitantly treated with drugs that are known to prolong the QT interval

Class IA antiarrhythmic agents, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with torsades de pointes-inducing medicinal products

Class IA antiarrhythmic agents, lumefantrine

The co-administration of medicinal products that prolong the interval QT is contraindicated

Class IA antiarrhythmic agents, lurasidone [2] ---> SmPC of [2] of EMA

Caution is advised when prescribing lurasidone with medicinal products known to prolong the QT interval

Class IA antiarrhythmic agents, macimorelin [2] ---> SmPC of [2] of EMA

Co-administration of macimorelin with medicinal products with a potential to induce torsades de pointes should be avoided

Class IA antiarrhythmic agents, macrolide antibiotics

Caution is warranted for concomitant use of QT interval prolonging medicines

Class IA antiarrhythmic agents, melperone

The co-administration of melperone with drugs that also prolong the QT interval should be avoided

Class IA antiarrhythmic agents, methadone

The risk of QT interval prolongation may be increased if methadone is administered with medicinal products affecting heart conduction

Class IA antiarrhythmic agents, metoprolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may have potentiating effects on atrial-conduction time and induce negative inotropic effect of metoprolol.

Class IA antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

The concomitant use of mexiletine and antiarrhythmic medicines inducing torsades de pointes is contraindicated

Class IA antiarrhythmic agents, mizolastine [2] ---> SmPC of [2] of eMC

The co-administration of mizolastine with drugs that prolong the QT interval is contraindicated

Class IA antiarrhythmic agents, moclobemide

The co-administration of moclobemide with drugs that prolong the QT interval should be avoided

Class IA antiarrhythmic agents, moxifloxacin [2] ---> SmPC of [2] of eMC

The co-administration may have an additive effect on the QT interval prolongation. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. The combination is contraindicated.

Class IA antiarrhythmic agents, nadolol [2] ---> SmPC of [2] of eMC

Additive or antagonistic effects may occur with nadolol and antiarrhythmic agents.

Class IA antiarrhythmic agents, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Class IA antiarrhythmic agents, nebivolol [2] ---> SmPC of [2] of eMC

Combination not recommended as the effect on atrio-ventricular conduction time may be potentiated and the negative inotropic effect increased

Class IA antiarrhythmic agents, norfloxacin [2] ---> SmPC of [2] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class IA antiarrhythmic agents, nortriptyline

Concomitant use of nortriptyline with drugs known to prolong the QT interval should be avoided

Class IA antiarrhythmic agents, ofloxacin [2] ---> SmPC of [2] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class IA antiarrhythmic agents, opipramol

The co-administration may prolong the QT interval. Concomitant use should be avoided

Class IA antiarrhythmic agents, oxprenolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IA antiarrhythmic agents, paliperidone [2] ---> SmPC of [2] of EMA

Caution is advised when prescribing paliperidone with medicines known to prolong the QT interval

Class IA antiarrhythmic agents, pasireotide [2] ---> SmPC of [2] of EMA

Pasireotide should be used with caution in patients who are concomitantly receiving medicinal products that prolong the QT interval

Class IA antiarrhythmic agents, pentamidine [2] ---> SmPC of [2] of eMC

Caution is advised when pentamidine isetionate is concomitantly used with drugs that are known to prolong the QT interval

Class IA antiarrhythmic agents, perazine

The effect of perazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs should be avoided

Class IA antiarrhythmic agents, perphenazine

Concomitant use of perphenazine with QT prolonging drugs is not recommended.

Class IA antiarrhythmic agents, pimozide [2] ---> SmPC of [2] of eMC

Concomitant use of pimozide with drugs known to prolong the QT interval is contra-indicated

Class IA antiarrhythmic agents, pindolol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IA antiarrhythmic agents, pindolol/clopamide

Caution should be exercised in the concurrent use of beta-blocking agents with class 1 antiarrhythmics (e.g. disopyramide, quinidine) and amiodarone.

Class IA antiarrhythmic agents, pipamperone

The co-administration of drugs that can prolong the QT interval should be avoided

Class IA antiarrhythmic agents, piperaquine ---> SmPC of [piperaquine/artenimol] of EMA

The combination of piperaquine with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Class IA antiarrhythmic agents, piperaquine/artenimol [2] ---> SmPC of [2] of EMA

The combination of piperaquine/dihydroartemisinin with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Class IA antiarrhythmic agents, piretanide

There is an increased risk of heart rhythm disorders if piretanide is co-administered with drugs that may prolong the QT interval

Class IA antiarrhythmic agents, prajmalium

Prajmalium should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Class IA antiarrhythmic agents, promazine [2] ---> SmPC of [2] of eMC

Concomitant use of promazine with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore, concomitant use of these products is not recommended.

Class IA antiarrhythmic agents, promethazine

The co-administration of promethazine with drugs that also prolong the QT interval should be avoided

Class IA antiarrhythmic agents, propranolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IA antiarrhythmic agents, prothipendyl

Concomitant use of prothipendyl with drugs known to prolong the QT interval should be avoided

Class IA antiarrhythmic agents, QT interval prolonging drugs

Caution is advised with medicinal products that prolong the QT interval

Class IA antiarrhythmic agents, quinine

The co-administration of quinine with medicinal products that significant prolong the QT interval is contraindicated

Class IA antiarrhythmic agents, quinolones ---> SmPC of [norfloxacin] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class IA antiarrhythmic agents, ranolazine [2] ---> SmPC of [2] of EMA

Concomitant administration of class Ia antiarrhythmics with ranolazine is contraindicated

Class IA antiarrhythmic agents, risperidone [2] ---> SmPC of [2] of eMC

Caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval

Class IA antiarrhythmic agents, roxithromycin

Caution is warranted for concomitant use of roxitromycin with other QT interval prolonging medicines

Class IA antiarrhythmic agents, sertindole

Increases in the QT interval related to sertindole treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs is therefore contraindicated

Class IA antiarrhythmic agents, siponimod [2] ---> SmPC of [2] of EMA

Concomitant use of these substances during treatment initiation may be associated with severe bradycardia and heart block.

Class IA antiarrhythmic agents, sotalol [2] ---> SmPC of [2] of eMC

Sotalol should be given with extreme caution in conjunction with other drugs known to prolong the QT-interval. Drugs that prolong the QT-interval may cause torsades de pointes. The co-administration with sotalol is contraindicated

Class IA antiarrhythmic agents, sulpiride [2] ---> SmPC of [2] of eMC

The combination of sulpiride with class Ia antiarrhythmic agents is not recommended

Class IA antiarrhythmic agents, talinolol

Combined use of beta-adrenoceptor blocking drugs and calcium channel blockers with negative inotropic effects can lead to prolongation of SA and AV conduction. This may result in severe hypotension, bradycardia and cardiac failure.

Class IA antiarrhythmic agents, telaprevir [2] ---> SmPC of [2] of EMA

Concomitant administration of telaprevir with class Ia or III antiarrhythmics, except for intravenous lidocaine, is contraindicated

Class IA antiarrhythmic agents, telithromycin [2] ---> SmPC of [2] of EMA

Due to a potential to increase the QT interval, telithromycin should be used with care during concomitant administration with QT interval prolonging agents

Class IA antiarrhythmic agents, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended when MicardisPlus is administered with drugs affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and torsades de pointes inducing medicinal products

Class IA antiarrhythmic agents, terfenadine

The co-administration of terfenadine with antiarrthymics of class I or III is contraindicated

Class IA antiarrhythmic agents, terlipressin

Terlipressin can cause ventricular arrhythmias (incl. torsades de pointes). The combination with drugs that prolong the QT interval should be done with extreme caution

Class IA antiarrhythmic agents, tetrabenazine [2] ---> SmPC of [2] of eMC

Tetrabenazine should be used with caution with drugs known to prolong QTc

Class IA antiarrhythmic agents, tiapride

Tiapride should not be combined with drugs that prolong the QT interval. These drugs (with the exception of anti-infectious) should be discontinued, if possible, if they induce torsades de pointes

Class IA antiarrhythmic agents, tolterodine [2] ---> SmPC of [2] of eMC

Tolterodine should be used with caution in patients with risk factors for QT-prolongation

Class IA antiarrhythmic agents, toremifene [2] ---> SmPC of [2] of EMA

An additive effect on QT interval prolongation between toremifene and medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias. Co-administration is contraindicated

Class IA antiarrhythmic agents, trazodone [2] ---> SmPC of [2] of eMC

Concomitant use of trazodone with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are coadministered with trazodone.

Class IA antiarrhythmic agents, triamcinolone

Concomitant use of triamcinolone with class I antiarrhythmics is not recommended

Class IA antiarrhythmic agents, triamcinolone acetonide

Concomitant use of triamcinolone with class I antiarrhythmics is not recommended

Class IA antiarrhythmic agents, tricyclic antidepressant ---> SmPC of [imipramine] of eMC

Tricyclic antidepressants should not be employed in combination with anti-arrhythmic agents of the quinidine type.

Class IA antiarrhythmic agents, trimipramine

Additive QT-prolongation may occur, increasing the risk of serious ventricular arrhythmias. The co-administration should be used with caution

Class IA antiarrhythmic agents, vandetanib [2] ---> SmPC of [2] of EMA

The concomitant use of vandetanib with medicinal products known to also prolong the QTc interval and/or induce Torsades de pointes is either contraindicated or not recommended

Class IA antiarrhythmic agents, vardenafil [2] ---> SmPC of [2] of EMA

Medicinal products that may prolong QTc interval, including vardenafil, are best avoided in patients with relevant risk factors, for example concomitant administration of antiarrhythmic medicinal products in Class 1A

Class IA antiarrhythmic agents, vernakalant [2] ---> SmPC of [2] of EMA

The use of intravenous rhythm control antiarrhythmics (class I and III) within 4 hours prior to, as well as in the first 4 hours after, vernakalant administration is contraindicated

Class IA antiarrhythmic agents, xipamide

The combination increases the risk of ventricular arrhythmias, particularly torsades de pointes (favored by hypokaliemia). It is recommended a special caution

Class IA antiarrhythmic agents, ziprasidone

Additive QT-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.

Class IA antiarrhythmic agents, zuclopenthixol [2] ---> SmPC of [2] of eMC

Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided.

Class IB antiarrhythmic agents, doxepin

The co-administration of doxepin with drugs that can prolong the QT interval should be avoided

Class IB antiarrhythmic agents, dronedarone [2] ---> SmPC of [2] of EMA

Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias

Class IB antiarrhythmic agents, esmolol [2] ---> SmPC of [2] of eMC

Concomitant use of esmolol and class I antiarrhythmic agents can increase the action of both on the AV-conductance time and induce negative inotropic effect.

Class IB antiarrhythmic agents, flecainide [2] ---> SmPC of [2] of eMC

Flecainide should not be administered concomitantly with other class I antiarrhythmics.

Class IB antiarrhythmic agents, labetalol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IB antiarrhythmic agents, lacosamide [2] ---> SmPC of [2] of EMA

Lacosamide should be used with caution in patients treated with class I antiarrhythmic drugs

Class IB antiarrhythmic agents, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA

The risk of additional systemic toxicity should be considered when large doses of lidocaine/prilocaine are applied to patients already using other local anaesthetics or structurally related medicinal products

Class IB antiarrhythmic agents, metoprolol

Class I anti-arrhythmic drugs may have potentiating effects on atrial-conduction time and induce negative inotropic effect of metoprolol.

Class IB antiarrhythmic agents, metoprolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may have potentiating effects on atrial-conduction time and induce negative inotropic effect of metoprolol.

Class IB antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

Co-administration of mexiletine and other classes of antiarrhythmics (class Ib; class II; class IV) is not recommended, unless exceptionally, because of the increased risk of adverse cardiac reactions

Class IB antiarrhythmic agents, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Class IB antiarrhythmic agents, nebivolol [2] ---> SmPC of [2] of eMC

Combination not recommended as the effect on atrio-ventricular conduction time may be potentiated and the negative inotropic effect increased

Class IB antiarrhythmic agents, oxprenolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IB antiarrhythmic agents, pindolol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IB antiarrhythmic agents, pindolol/clopamide

Caution should be exercised in the concurrent use of beta-blocking agents with class 1 antiarrhythmics (e.g. disopyramide, quinidine) and amiodarone.

Class IB antiarrhythmic agents, prajmalium

Prajmalium should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Class IB antiarrhythmic agents, prilocaine

The risk of additional systemic toxicity should be considered

Class IB antiarrhythmic agents, propranolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IB antiarrhythmic agents, talinolol

Combined use of beta-adrenoceptor blocking drugs and calcium channel blockers with negative inotropic effects can lead to prolongation of SA and AV conduction. This may result in severe hypotension, bradycardia and cardiac failure.

Class IB antiarrhythmic agents, terfenadine

The co-administration of terfenadine with antiarrthymics of class I or III is contraindicated

Class IB antiarrhythmic agents, vernakalant [2] ---> SmPC of [2] of EMA

The use of intravenous rhythm control antiarrhythmics (class I and III) within 4 hours prior to, as well as in the first 4 hours after, vernakalant administration is contraindicated

Class IC antiarrhythmic agents, doxepin

The co-administration of doxepin with drugs that can prolong the QT interval should be avoided

Class IC antiarrhythmic agents, dronedarone [2] ---> SmPC of [2] of EMA

Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias

Class IC antiarrhythmic agents, esmolol [2] ---> SmPC of [2] of eMC

Concomitant use of esmolol and class I antiarrhythmic agents can increase the action of both on the AV-conductance time and induce negative inotropic effect.

Class IC antiarrhythmic agents, flecainide [2] ---> SmPC of [2] of eMC

Flecainide should not be administered concomitantly with other class I antiarrhythmics.

Class IC antiarrhythmic agents, labetalol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IC antiarrhythmic agents, lacosamide [2] ---> SmPC of [2] of EMA

Lacosamide should be used with caution in patients treated with class I antiarrhythmic drugs

Class IC antiarrhythmic agents, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA

The risk of additional systemic toxicity should be considered when large doses of lidocaine/prilocaine are applied to patients already using other local anaesthetics or structurally related medicinal products

Class IC antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

The concomitant use of mexiletine and antiarrhythmic medicines inducing torsades de pointes is contraindicated

Class IC antiarrhythmic agents, mirabegron [2] ---> SmPC of [2] of EMA

Caution is advised if mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6. Caution is also advised with CYP2D6 substrates that are individually dose titrated.

Class IC antiarrhythmic agents, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Class IC antiarrhythmic agents, nebivolol [2] ---> SmPC of [2] of eMC

Combination not recommended as the effect on atrio-ventricular conduction time may be potentiated and the negative inotropic effect increased

Class IC antiarrhythmic agents, oxprenolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IC antiarrhythmic agents, pindolol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IC antiarrhythmic agents, pindolol/clopamide

Caution should be exercised in the concurrent use of beta-blocking agents with class 1 antiarrhythmics (e.g. disopyramide, quinidine) and amiodarone.

Class IC antiarrhythmic agents, prajmalium

Prajmalium should not be co-administrated with other class I antiarrhythmic medicinal products due to risk of severe adverse effects

Class IC antiarrhythmic agents, propranolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IC antiarrhythmic agents, sertraline [2] ---> SmPC of [2] of EMA

Clinical relevant interactions may occur with other CYP 2D6 substrates with a narrow therapeutic index, especially at higher sertraline dose levels.

Class IC antiarrhythmic agents, talinolol

Combined use of beta-adrenoceptor blocking drugs and calcium channel blockers with negative inotropic effects can lead to prolongation of SA and AV conduction. This may result in severe hypotension, bradycardia and cardiac failure.

Class IC antiarrhythmic agents, terfenadine

The co-administration of terfenadine with antiarrthymics of class I or III is contraindicated

Class IC antiarrhythmic agents, vernakalant [2] ---> SmPC of [2] of EMA

The use of intravenous rhythm control antiarrhythmics (class I and III) within 4 hours prior to, as well as in the first 4 hours after, vernakalant administration is contraindicated

Class II antiarrhythmic agents, disopyramide [2] ---> SmPC of [2] of eMC

Antiarrhythmic combination should be avoided except under certain circumstances

Class II antiarrhythmic agents, flecainide [2] ---> SmPC of [2] of eMC

The possibility of additive negative inotropic effects of class II antiarrhythmics, i.e. beta-blockers, with flecainide should be recognised.

Class II antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

Co-administration of mexiletine and other classes of antiarrhythmics (class Ib; class II; class IV) is not recommended, unless exceptionally, because of the increased risk of adverse cardiac reactions

Class III antiarrhythmic agents [1], flupentixol ---> SmPC of [1] of eMC

Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided.

Class III antiarrhythmic agents, clomipramine [2] ---> SmPC of [2] of eMC

The risk of QTc prolongation and Torsade de Pointes is likely to be increased if clomipramine is co-administered with other drugs that can cause QTc prolongation. Therefore concomitant use is not recommended

Class III antiarrhythmic agents, crizotinib [2] ---> SmPC of [2] of EMA

Concomitant use of crizotinib (prolongs QT interval) with medicinal products known to prolong QT interval or medicinal products able to induce Torsades de pointes should be carefully considered.

Class III antiarrhythmic agents, darolutamide [2] ---> SmPC of [2] of EMA

Since androgen deprivation treatment may prolong the QT interval, the co-administration with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes should be carefully evaluated.

Class III antiarrhythmic agents, degarelix [2] ---> SmPC of [2] of EMA

The combination of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes should be carefully evaluated

Class III antiarrhythmic agents, dimenhydrinate

The concurrent use of dimenhydrinate and drugs that also prolong the QT interval should be avoided

Class III antiarrhythmic agents, diphenhydramine

The co-administration is contraindicated

Class III antiarrhythmic agents, disopyramide [2] ---> SmPC of [2] of eMC

Antiarrhythmic combination should be avoided except under certain circumstances

Class III antiarrhythmic agents, dofetilide [2] ---> SmPC of [2] of EMA

The co-administration of dofetilide with drugs known to prolong the QT interval is contraindicated

Class III antiarrhythmic agents, doxepin

The co-administration of doxepin with drugs that can prolong the QT interval should be avoided

Class III antiarrhythmic agents, dronedarone [2] ---> SmPC of [2] of EMA

Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias

Class III antiarrhythmic agents, droperidol [2] ---> SmPC of [2] of eMC

Medicinal products known to prolong the QTc interval should not be concomitantly administered with droperidol.

Class III antiarrhythmic agents, efavirenz/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes

Class III antiarrhythmic agents, eliglustat [2] ---> SmPC of [2] of EMA

Because eliglustat is predicted to cause mild increases in ECG intervals at substantially elevated plasma concentrations, use of eliglustat should be avoided in combination with Class IA and Class III antiarrhythmic medicinal products.

Class III antiarrhythmic agents, enzalutamide [2] ---> SmPC of [2] of EMA

The concomitant use of enzalutamide with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes should be carefully evaluated

Class III antiarrhythmic agents, eribulin [2] ---> SmPC of [2] of EMA

ECG monitoring is recommended if therapy is initiated in patients with concomitant treatment with medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities.

Class III antiarrhythmic agents, erythromycin

Patients receiving erythromycin concurrently with drugs which can cause prolongation of the QT interval should be carefully monitored; the concomitant use of erythromycin with some of these drugs is contraindicated

Class III antiarrhythmic agents, escitalopram [2] ---> SmPC of [2] of eMC

Co-administration of escitalopram with medicinal products that prolong the QT-interval is contraindicated.

Class III antiarrhythmic agents, fingolimod [2] ---> SmPC of [2] of EMA

Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate because of the potential additive effects on heart rate

Class III antiarrhythmic agents, fluconazole

Cases of QTc interval prolongation and/ or torsades de pointes may occur after concomitant use of fluconazole with some anti-arrhythmics

Class III antiarrhythmic agents, fluphenazine [2] ---> SmPC of [2] of eMC

The effect of fluphenazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs and fluphenazine is contraindicated.

Class III antiarrhythmic agents, furosemide

Electrolyte imbalance may enhance the toxicity of antiarrhythmic agent. Monitoring of serum potassium and ECG is recommended

Class III antiarrhythmic agents, gatifloxacin

The co-administration of gatifloxacin with medicinal products that prolong the QT interval should be avoided

Class III antiarrhythmic agents, gemifloxacin

The co-administration of gemifloxacin with medicinal products that prolong the QT interval should be avoided

Class III antiarrhythmic agents, haloperidol [2] ---> SmPC of [2] of eMC

Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended

Class III antiarrhythmic agents, hydrochlorothiazide ---> SmPC of [losartan/hydrochlorothiazide] of eMC

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Class III antiarrhythmic agents, hydroquinidine

Concomitant use of hydroquinidine with drugs that can induce torsades de pointes is contraindicated due to increased risk of heart rhythm disorders (torsades de pointes)

Class III antiarrhythmic agents, hydroxyzine [2] ---> SmPC of [2] of eMC

Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes increase the risk of cardiac arrhythmia. Therefore, the combination is contra-indicated

Class III antiarrhythmic agents, ibutilide

Possible prolongation of refractory period. Contraindicated: Combination, administration within 4 hours after infusion and only if the QTc has returned to its basal value

Class III antiarrhythmic agents, imipramine

Tricyclic antidepressants should not be employed in combination with anti-arrhythmic agents of the amiodarone type.

Class III antiarrhythmic agents, indapamide [2] ---> SmPC of [2] of eMC

The co-administration may increase the risk of ventricular arrhythmias, particularly torsades de pointes (hypokalemia is a risk factor)

Class III antiarrhythmic agents, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended, when hydrochlorothiazide is administered with drugs which may induce torsades de pointes

Class III antiarrhythmic agents, lenvatinib [2] ---> SmPC of [2] of EMA

Electrocardiograms should be monitored in patients taking medicinal products known to prolong the QT interval

Class III antiarrhythmic agents, lercanidipine [2] ---> SmPC of [2] of eMC

Caution should be exercised when lercanidipine is co-prescribed with other substrates of CYP3A4

Class III antiarrhythmic agents, levobupivacaine [2] ---> SmPC of [2] of eMC

Levobupivacaine should be used with caution in patients receiving class III anti-arrhythmic agents since their toxic effects may be additive.

Class III antiarrhythmic agents, levofloxacin [2] ---> SmPC of [2] of EMA

Levofloxacin should be used with caution in patients receiving active substances known to prolong the QT interval

Class III antiarrhythmic agents, levomepromazine [2] ---> SmPC of [2] of eMC

There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval

Class III antiarrhythmic agents, lidocaine [2] ---> SmPC of [2] of eMC

Specific interaction studies with lidocaine and class III anti-arrhythmic drugs (e.g. amiodarone) have not been performed, but caution is advised.

Class III antiarrhythmic agents, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA

Patients on anti-arrhythmic medicinal products class III should be treated with caution.

Class III antiarrhythmic agents, lithium ---> SmPC of [lithium carbonate] of eMC

As a precautionary measure, lithium should be avoided in patients concomitantly treated with drugs that are known to prolong the QT interval

Class III antiarrhythmic agents, lithium carbonate [2] ---> SmPC of [2] of eMC

As a precautionary measure, lithium should be avoided in patients concomitantly treated with drugs that are known to prolong the QT interval

Class III antiarrhythmic agents, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with torsades de pointes-inducing medicinal products

Class III antiarrhythmic agents, lumefantrine

The co-administration of medicinal products that prolong the interval QT is contraindicated

Class III antiarrhythmic agents, lurasidone [2] ---> SmPC of [2] of EMA

Caution is advised when prescribing lurasidone with medicinal products known to prolong the QT interval

Class III antiarrhythmic agents, macimorelin [2] ---> SmPC of [2] of EMA

Co-administration of macimorelin with medicinal products with a potential to induce torsades de pointes should be avoided

Class III antiarrhythmic agents, macrolide antibiotics

Caution is warranted for concomitant use of QT interval prolonging medicines

Class III antiarrhythmic agents, melperone

The co-administration of melperone with drugs that also prolong the QT interval should be avoided

Class III antiarrhythmic agents, mepivacaine

The co-administration of mepivacaine with class III antiarrhythmic agents (e. g. amiodarone) should be done with close observation and ECG monitoring due to cardiac effects can be additives

Class III antiarrhythmic agents, methadone

The risk of QT interval prolongation may be increased if methadone is administered with medicinal products affecting heart conduction

Class III antiarrhythmic agents, metoprolol [2] ---> SmPC of [2] of eMC

Class I anti-arrhythmic drugs may have potentiating effects on atrial-conduction time and induce negative inotropic effect of metoprolol.

Class III antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

The concomitant use of mexiletine and antiarrhythmic medicines inducing torsades de pointes is contraindicated

Class III antiarrhythmic agents, mizolastine [2] ---> SmPC of [2] of eMC

The co-administration of mizolastine with drugs that prolong the QT interval is contraindicated

Class III antiarrhythmic agents, moclobemide

The co-administration of moclobemide with drugs that prolong the QT interval should be avoided

Class III antiarrhythmic agents, moxifloxacin [2] ---> SmPC of [2] of eMC

The co-administration may have an additive effect on the QT interval prolongation. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. The combination is contraindicated.

Class III antiarrhythmic agents, naftidrofuryl

Naftidrofuryl may potentiate the effect of antiarrhythmic agent

Class III antiarrhythmic agents, nebivolol [2] ---> SmPC of [2] of eMC

The concomitant use should be done with caution as the effect on atrioventricular conduction time may be potentiated

Class III antiarrhythmic agents, norfloxacin [2] ---> SmPC of [2] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class III antiarrhythmic agents, nortriptyline

Concomitant use of nortriptyline with drugs known to prolong the QT interval should be avoided

Class III antiarrhythmic agents, ofloxacin [2] ---> SmPC of [2] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class III antiarrhythmic agents, opipramol

The co-administration may prolong the QT interval. Concomitant use should be avoided

Class III antiarrhythmic agents, oxprenolol

Class III anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with oxprenolol.

Class III antiarrhythmic agents, paliperidone [2] ---> SmPC of [2] of EMA

Caution is advised when prescribing paliperidone with medicines known to prolong the QT interval

Class III antiarrhythmic agents, pasireotide [2] ---> SmPC of [2] of EMA

Pasireotide should be used with caution in patients who are concomitantly receiving medicinal products that prolong the QT interval

Class III antiarrhythmic agents, pentamidine [2] ---> SmPC of [2] of eMC

Caution is advised when pentamidine isetionate is concomitantly used with drugs that are known to prolong the QT interval

Class III antiarrhythmic agents, perazine

The effect of perazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs should be avoided

Class III antiarrhythmic agents, perphenazine

Concomitant use of perphenazine with QT prolonging drugs is not recommended.

Class III antiarrhythmic agents, pimozide [2] ---> SmPC of [2] of eMC

Concomitant use of pimozide with drugs known to prolong the QT interval is contra-indicated

Class III antiarrhythmic agents, pipamperone

The co-administration of drugs that can prolong the QT interval should be avoided

Class III antiarrhythmic agents, piperaquine ---> SmPC of [piperaquine/artenimol] of EMA

The combination of piperaquine with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Class III antiarrhythmic agents, piperaquine/artenimol [2] ---> SmPC of [2] of EMA

The combination of piperaquine/dihydroartemisinin with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval

Class III antiarrhythmic agents, piretanide

There is an increased risk of heart rhythm disorders if piretanide is co-administered with drugs that may prolong the QT interval

Class III antiarrhythmic agents, prilocaine

The heart effects may be additive.

Class III antiarrhythmic agents, promazine [2] ---> SmPC of [2] of eMC

Concomitant use of promazine with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore, concomitant use of these products is not recommended.

Class III antiarrhythmic agents, promethazine

The co-administration of promethazine with drugs that also prolong the QT interval should be avoided

Class III antiarrhythmic agents, prothipendyl

Concomitant use of prothipendyl with drugs known to prolong the QT interval should be avoided

Class III antiarrhythmic agents, QT interval prolonging drugs

Caution is advised with medicinal products that prolong the QT interval

Class III antiarrhythmic agents, quinine

The co-administration of quinine with medicinal products that significant prolong the QT interval is contraindicated

Class III antiarrhythmic agents, quinolones ---> SmPC of [norfloxacin] of eMC

The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval

Class III antiarrhythmic agents, ranolazine [2] ---> SmPC of [2] of EMA

Concomitant administration of class III antiarrhythmics (other than amiodarone) with ranolazine is contraindicated

Class III antiarrhythmic agents, risperidone [2] ---> SmPC of [2] of eMC

Caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval

Class III antiarrhythmic agents, rivastigmine [2] ---> SmPC of [2] of EMA

Caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents

Class III antiarrhythmic agents, ropivacaine [2] ---> SmPC of [2] of eMC

Specific interaction studies with ropivacaine and anti-arrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised

Class III antiarrhythmic agents, roxithromycin

Caution is warranted for concomitant use of roxitromycin with other QT interval prolonging medicines

Class III antiarrhythmic agents, sertindole

Increases in the QT interval related to sertindole treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs is therefore contraindicated

Class III antiarrhythmic agents, siponimod [2] ---> SmPC of [2] of EMA

Concomitant use of these substances during treatment initiation may be associated with severe bradycardia and heart block.

Class III antiarrhythmic agents, sotalol [2] ---> SmPC of [2] of eMC

Sotalol should be given with extreme caution in conjunction with other drugs known to prolong the QT-interval. Drugs that prolong the QT-interval may cause torsades de pointes. The co-administration with sotalol is contraindicated

Class III antiarrhythmic agents, sulpiride [2] ---> SmPC of [2] of eMC

The combination of sulpiride with class III antiarrhythmic agents is not recommended

Class III antiarrhythmic agents, telaprevir [2] ---> SmPC of [2] of EMA

Concomitant administration of telaprevir with class Ia or III antiarrhythmics, except for intravenous lidocaine, is contraindicated

Class III antiarrhythmic agents, telithromycin [2] ---> SmPC of [2] of EMA

Due to a potential to increase the QT interval, telithromycin should be used with care during concomitant administration with QT interval prolonging agents

Class III antiarrhythmic agents, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Periodic monitoring of serum potassium and ECG is recommended when MicardisPlus is administered with drugs affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and torsades de pointes inducing medicinal products

Class III antiarrhythmic agents, terfenadine

The co-administration of terfenadine with antiarrthymics of class I or III is contraindicated

Class III antiarrhythmic agents, terlipressin

Terlipressin can cause ventricular arrhythmias (incl. torsades de pointes). The combination with drugs that prolong the QT interval should be done with extreme caution

Class III antiarrhythmic agents, tetrabenazine [2] ---> SmPC of [2] of eMC

Tetrabenazine should be used with caution with drugs known to prolong QTc

Class III antiarrhythmic agents, tiapride

Tiapride should not be combined with drugs that prolong the QT interval. These drugs (with the exception of anti-infectious) should be discontinued, if possible, if they induce torsades de pointes

Class III antiarrhythmic agents, tolterodine [2] ---> SmPC of [2] of eMC

Tolterodine should be used with caution in patients with risk factors for QT-prolongation

Class III antiarrhythmic agents, toremifene [2] ---> SmPC of [2] of EMA

An additive effect on QT interval prolongation between toremifene and medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias. Co-administration is contraindicated

Class III antiarrhythmic agents, trazodone [2] ---> SmPC of [2] of eMC

Concomitant use of trazodone with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are coadministered with trazodone.

Class III antiarrhythmic agents, triamcinolone

Concomitant use of triamcinolone with class III antiarrhythmics is not recommended

Class III antiarrhythmic agents, triamcinolone acetonide

Concomitant use of triamcinolone with class III antiarrhythmics is not recommended

Class III antiarrhythmic agents, trimipramine

Additive QT-prolongation may occur, increasing the risk of serious ventricular arrhythmias. The co-administration should be used with caution

Class III antiarrhythmic agents, vandetanib [2] ---> SmPC of [2] of EMA

The concomitant use of vandetanib with medicinal products known to also prolong the QTc interval and/or induce Torsades de pointes is either contraindicated or not recommended

Class III antiarrhythmic agents, vardenafil [2] ---> SmPC of [2] of EMA

Medicinal products that may prolong QTc interval, including vardenafil, are best avoided in patients with relevant risk factors, for example concomitant administration of antiarrhythmic medicinal products in Class III

Class III antiarrhythmic agents, vernakalant [2] ---> SmPC of [2] of EMA

The use of intravenous rhythm control antiarrhythmics (class I and III) within 4 hours prior to, as well as in the first 4 hours after, vernakalant administration is contraindicated

Class III antiarrhythmic agents, xipamide

The combination increases the risk of ventricular arrhythmias, particularly torsades de pointes (favored by hypokaliemia). It is recommended a special caution

Class III antiarrhythmic agents, ziprasidone

Additive QT-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.

Class III antiarrhythmic agents, zuclopenthixol [2] ---> SmPC of [2] of eMC

Increases in the QT interval related to antipsychotic treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs should be avoided.

Class IV antiarrhythmic agents, disopyramide [2] ---> SmPC of [2] of eMC

Antiarrhythmic combination should be avoided except under certain circumstances

Class IV antiarrhythmic agents, labetalol

Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.

Class IV antiarrhythmic agents, mexiletine [2] ---> SmPC of [2] of EMA

Co-administration of mexiletine and other classes of antiarrhythmics (class Ib; class II; class IV) is not recommended, unless exceptionally, because of the increased risk of adverse cardiac reactions